Przybyla, Anna http://orcid.org/0000-0002-6395-5731
Zhang, Ting
Li, Ruliang
Roen, Diana R.
Mackiewicz, Andrzej
Lehmann, Paul V.
Funding for this research was provided by:
National Centre for Research and Development (Innomed: Personalization of melanoma therapeutic vaccination. Innomed/I/6/NCBR/2014)
Research Budget of CTL
Article History
Received: 9 April 2018
Accepted: 24 December 2018
First Online: 19 February 2019
Compliance with ethical standards
:
: Paul V. Lehmann is founder and CEO of CTL, a company that specializes on immune monitoring via ELISPOT. Ting Zhang, Ruliang Li., and Diana R. Roen are CTL employees. Anna Przybyla and Andrzej Mackiewicz declare that they have no conflict of interest.
: The PBMC of healthy human donors used in this study were obtained from CTL’s ePBMC bank. (ExternalRef removed, Cleveland, OH, USA). These cells were isolated from blood purchased from Hemacare (Van Nuys, CA, USA) under Hemacare’s IRB. Hemacare obtained the informed consents from healthy blood donors.
: This article does not contain any studies involving patients or experimental animals.
: PBMC from healthy human donors used for this study were collected with IRB approval.